The results showed that the anti-tumor effects of combined IL-2 with PD-1 blockade in March5+/f:Vav1-Cre mice were superior to that in March5+/f mice, which eliminated tumors in 2 out of 8 March5+/f:Vav1-Cre mice (Fig. 6f, g). This evidence concerns the gene VAV1 and neoplasm.